European Psychiatry - Volume 33 - March 2016

372 / 812

S368 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805
2 Research Unit of Clinical Alcohol Research, University of Southern
Denmark, Odense, Denmark
3 Orthopaedic Department, Odense University Hospital, Odense,
Denmark
∗ Corresponding author.
Introduction Exercise addiction is characterized by increasing
exercise amounts, withdrawal symptoms and lack of control. Exer-
cisers with addiction continue to exercise in spite of pain and injury
because they use exercise to regulate emotions, identity and self-
esteem. How do they react to injuries?
Objectives It is hypothesized that exercise addiction is a risk fac-
tor for emotional distress when an injury occur due to withdrawal
symptoms and lack of identity.
Aims To estimate the prevalence of exercise addiction in exer-
cisers with injuries at the musculoskeletal system and to test the
relationship between addiction and emotional distress (depression
and stress).
Methods The Exercise Addiction Inventory was used to identify
exercise addiction. To measure depression and stress we used the
Major Depression Inventory (MDI) and the Perceived Stress Scale
(PSS). Participants (n = 694) were regular exercisers with injuries at
foot, knee or shoulder at an orthopedic hospital department.
Results The prevalence of exercise addiction was 7.6%. We found
that exercisers with addiction reported more emotional distress in
terms of higher MDI-scores 18.0 (SD = 11.0) versus 11.7 (SD = 9.1);
P = 0.00 and in total PSS-score 17.6 (SD = 7.2) versus 13.9 (SD = 6.8);
P = 0.00. Chi2 analyses showed that 25% of the addicted exercisers
met the criteria for clinical depression, while only 11% of the non-
addicted exercisers were depressed; P = 0.00.
Conclusions Exercisers with addiction appear at somatic depart-
ments treating musculoskeletal injuries. It is a vulnerable group
characterized by elevated levels of depressive symptoms and clin-
ical stress. We recommend to offer psychological interventions
focusing on emotional distress and prevention of re-injury by
reducing excessive and obsessive exercise patterns.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV58
Qualitative study of patients with dual
pathology in treatment with
aripiprazole extended-release
injectable suspension
L. Fernández Mayo ∗, D. Ba˜no Rodrigo , E. Barbero García ,
M. Agujetas Rodriguez
CAID Majadahonda, Center for Attention to drug addicts,
Majadahonda, Madrid, Spain
∗ Corresponding author.
Introduction Studies describe patients with dual pathology as
subjects with worse clinical evolution and worse therapeutic
response. These subjects have high percentages of worse thera-
peutic compliance and low adherence to psychopharmacological
treatment. The conventional antipsychotics can induce dyspho-
ria and worse craving and drug use. The long duration-injectable
antipsychotics could serve as a good therapeutic alternative
because they combine efficacy and tolerability.
Objectives We analyzed subjects treated with aripiprazole
injectable to demonstrate its effectiveness on symptomatology, the
reduction of craving and consumption of substances.
Materials and methods We studied subjects with dual disorders
at a Center for Attention to drug addicts treated with aripiprazole
extended-release injectable. All of them met criteria for the diag-
nosis of disorders for cannabis and cocaine use. All of them had
been previously treated with oral antipsychotics and/or injectable
of long duration. Evolution of craving and consumption were eval-
uated through clinical interviews and urine analysis.
Results Cannabis was the main substance for all the patients.
Three of them also often abused of cocaine. All of themwere taking
other treatments previously. The main causes of the change were:
side effects and/or poor compliance. Only one patient discontinued
follow-up. The rest of them showed good therapeutic adherence
and better tolerability with aripiprazole injectable. The monthly
dose was 400mg.
Conclusions Aripiprazole extended-release injectable is a good
choice for dual disorders. A good therapeutic adherence involves
not only a psychopathological improvement but also respect to
craving and consumption, which makes aripiprazole injectable a
suitable therapeutic option.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV59
Nalmefene and alcohol use disorder.
Evaluation of clinical cases at a
treatment centre for drug addicts
L. Fernández Mayo ∗, D. Ba˜no Rodrigo , E. Barbero García ,
M. Agujetas Rodríguez
CAID Majadahonda, Treatment Centre for Drug Addicts,
Majadahonda, Madrid, Spain
∗ Corresponding author.
Introduction Alcohol abuse causes dopamine release in the
mesolimbic system, which activates the reward circuit. This is
linked to an interdependent opioid, serotonergic and endocannabi-
noid system. Nalmefene is a modulator of the endogenous opioid
system, with antagonistic effect on mu and delta receptors, and a
partial agonist activity kappa. This means that reduces the reinforc-
ing effects of alcohol consumption through the cortical-mesolimbic
system. Therefore, when a patient takes nalmefene, the satisfaction
obtained when he drinks is lower, which increases the possibility
to have more control over drinking.
The efficacy of nalmefene was evaluated in two profiles of patients:
1. No abstinence in alcohol dependence disorder and continu-
ous relapses, 2. Cocaine dependence disorder associated to alcohol
abuse.
Objectives Improving the quality of life and compliance rates due
to the difficulties of following a strict treatment to achieve the absti-
nence. Furthermore, in cases of patients with cocaine dependence
disorder and alcohol abuse, the objective is to avoid cocaine use by
reducing previous alcohol consumption.
Conclusion nalmefene offers the possibility of treating the addic-
tion from a new perspective. Our current clinical experience has
been able to treat subjects with conventional treatments failures
and those who need to achieve the necessary control to reduce
cocaine use.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV60
Aripiprazole oral treatment in a
sample of patients with dual diagnosis
C. Llanes Álvarez ∗, A. San Román Uría , A. Caldero Alonso ,
M.Á. Garzón de Paz , M.Á. Franco Martín
1 Complejo Asistencial de Zamora, Psiquiatría, Zamora, Spain
2 Hospital Los Montalvos. Unidad Regional de Patología Dual,
Hospital Universitario de Salamanca, Psiquiatría, Salamanca, Spain
∗ Corresponding author.